Balaji Gandhi Sells 7,778 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 7,778 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $175,938.36. Following the transaction, the chief financial officer now directly owns 98,178 shares of the company’s stock, valued at approximately $2,220,786.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Monday, March 25th, Balaji Gandhi sold 3,504 shares of Phreesia stock. The shares were sold at an average price of $23.21, for a total transaction of $81,327.84.
• On Tuesday, January 16th, Balaji Gandhi sold 932 shares of Phreesia stock. The shares were sold at an average price of $24.55, for a total transaction of $22,880.60.

Phreesia Trading Up 2.1 %

PHR opened at $23.80 on Friday. Phreesia, Inc. has a 1-year low of $12.05 and a 1-year high of $34.98. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.34 billion, a P/E ratio of -9.44 and a beta of 0.92. The company has a fifty day moving average price of $24.76 and a two-hundred day moving average price of $21.09.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.02. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The firm had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. During the same period in the previous year, the firm posted ($0.72) earnings per share. The business’s revenue was up 24.0% compared to the same quarter last year. Analysts predict that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHR has been the subject of several analyst reports. Raymond James reaffirmed an “outperform” rating and set a $30.00 price target (up previously from $25.00) on shares of Phreesia in a research note on Friday, March 15th. Canaccord Genuity Group lifted their target price on shares of Phreesia from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Robert W. Baird lifted their target price on shares of Phreesia from $30.00 to $31.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. Stephens reissued an “overweight” rating and set a $28.00 target price on shares of Phreesia in a research note on Friday, March 22nd. Finally, Barclays initiated coverage on shares of Phreesia in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $29.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average price target of $31.62.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Moody National Bank Trust Division grew its holdings in shares of Phreesia by 41.9% during the first quarter. Moody National Bank Trust Division now owns 71,044 shares of the company’s stock valued at $1,700,000 after buying an additional 20,977 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Phreesia by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock valued at $107,148,000 after buying an additional 194,035 shares during the last quarter. American International Group Inc. grew its holdings in shares of Phreesia by 2.3% during the fourth quarter. American International Group Inc. now owns 26,342 shares of the company’s stock valued at $610,000 after buying an additional 591 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Phreesia by 56.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 74,595 shares of the company’s stock valued at $1,728,000 after buying an additional 26,868 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Phreesia by 376.7% during the fourth quarter. Barclays PLC now owns 88,531 shares of the company’s stock valued at $2,048,000 after buying an additional 69,959 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.